Importantly, SHP2 inhibition also overcomes adaptive resistance to RAS/MAPK pathway inhibitors in multiple cancer models by interfering with RTK-mediated RAS reactivation (12, 22, 24, 25, 27, 30–35). Here, PTPN11 is linked to cancer.